Immunology and Microbiology
Immunoglobulin E
100%
Allergen
85%
Birch
50%
Molecular Weight
33%
Squamous Cell
28%
ELISA
26%
Hypersensitive Response
25%
Talimogene Laherparepvec
25%
Permeability Barrier
25%
Holocephali
25%
Nicotiana benthamiana
25%
Cell Invasion
25%
Extract
25%
Allergenicity
25%
Sorafenib
25%
Single-Chain Variable Fragment
25%
Peptide Library
25%
Notch
25%
Lactobacillus buchneri
25%
Antigen Presentation
25%
Nose Mucosa
25%
Western Blot
22%
Basophil
22%
Sensitization
19%
Cross-Reactive Carbohydrate Determinants
16%
Biopanning
15%
EC50
12%
Gel Mobility Shift Assay
12%
Genetic Transcription
12%
Immune Response
10%
Nivolumab
8%
Somatic Cell
8%
Pistachio
8%
Artemisia vulgaris
8%
Immunoglobulin E Antibody
8%
Chondroitin Sulfate Proteoglycan
8%
Fluorescence Activated Cell Sorting
8%
Melanoma Cell Line
8%
MAPK Signaling
8%
Mediator
8%
Plant-Based Food
8%
Anaphylaxis
8%
Basophil Granulocyte
6%
Escherichia coli
6%
Histamine Release
6%
Pollen Allergy
6%
Cross-Reactivity
6%
Comorbidity
6%
Gene Expression System
5%
Atlantic Cod
5%
Medicine and Dentistry
Melanoma
57%
Neoplasm
28%
Metastatic Melanoma
28%
Skin Carcinoma
25%
Proteochondroitin Sulfate
25%
B Cell
25%
Sorafenib
25%
Hepatocellular Carcinoma
25%
Cancer Therapy
25%
Therapy Resistance
25%
Tumour Heterogeneity
25%
DNA Repair
25%
Mammalian Cell
25%
Skin Biopsy
25%
Trametinib
25%
Notch Signaling
25%
In Vitro
20%
Biopsy Technique
18%
Cell Membrane
8%
Cell Line
8%
Aneuploidy
8%
HaCaT
8%
Incubation
8%
Keratinocyte
8%
Deuterium Oxide
8%
Cell Proliferation
8%
Basophil Cell
8%
Carcinoma Cell
7%
Colony Formation
7%
In Silico
7%
MEK Inhibitor
6%
Diagnostic Error
6%
Disease Course
6%
Carbene
6%
Growth Factor
6%
Comorbidity
6%
Drug Resistance
6%
Cemiplimab
6%
Malignant Neoplasm
6%
Pembrolizumab
6%
Phosphotransferase Inhibitor
6%
Personalized Diagnosis
5%
Pharmacology, Toxicology and Pharmaceutical Science
Metastatic Melanoma
35%
Trametinib
28%
Dabrafenib
28%
EC50
25%
Talimogene Laherparepvec
25%
Progression Free Survival
25%
Aminolevulinic Acid
25%
Melanoma
25%
Hemosiderin
25%
Sorafenib
25%
Chondroitin Sulfate
25%
Gene Delivery
25%
Skin Carcinoma
25%
Lactobacillus buchneri
25%
Overall Survival
20%
Nivolumab
16%
Survival Rate
15%
Disease
15%
Lactate Dehydrogenase
10%
Lung Metastasis
10%
Avelumab
8%
Atezolizumab
8%
Cemiplimab
6%
Clinical Trial
5%
Bone Metastasis
5%
Cancer Staging
5%
Tolerability
5%
Observational Study
5%